Literature DB >> 18836475

NKG2D ligands in tumor immunity.

N Nausch1, A Cerwenka.   

Abstract

The activating receptor NKG2D (natural-killer group 2, member D) and its ligands play an important role in the NK, gammadelta(+) and CD8(+) T-cell-mediated immune response to tumors. Ligands for NKG2D are rarely detectable on the surface of healthy cells and tissues, but are frequently expressed by tumor cell lines and in tumor tissues. It is evident that the expression levels of these ligands on target cells have to be tightly regulated to allow immune cell activation against tumors, but at the same time avoid destruction of healthy tissues. Importantly, it was recently discovered that another safeguard mechanism controlling activation via the receptor NKG2D exists. It was shown that NKG2D signaling is coupled to the IL-15 receptor pathway in a cell-specific manner suggesting that priming of NKG2D-mediated activation depends on the cellular microenvironment and the distinct cellular context. This review will provide a broad overview of our up-to-date knowledge of the NKG2D receptor and its ligands in the context of tumor immunology. Strategies to amplify NKG2D-mediated antitumor responses and counteract tumor immune escape mechanisms will be discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836475     DOI: 10.1038/onc.2008.272

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  173 in total

1.  Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.

Authors:  Anindya Dasgupta; Jordan E Shields; H Trent Spencer
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

2.  Strain-dependent Lethal Toxicity in NKG2D Ligand-targeted CAR T-cell Therapy.

Authors:  Rachel C Lynn; Daniel J Powell
Journal:  Mol Ther       Date:  2015-10       Impact factor: 11.454

3.  The breast tumor microenvironment alters the phenotype and function of natural killer cells.

Authors:  Tamara Krneta; Amy Gillgrass; Marianne Chew; Ali A Ashkar
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

4.  Immobilized MHC class I chain-related protein A synergizes with IL-15 and soluble 4-1BB ligand to expand NK cells with high cytotoxicity ex vivo.

Authors:  Weijuan Gong; Weiming Xiao; Li Qian; Chunxiang Gong; Maozhi Hu; Xianyuan Pan; Mingchun Ji
Journal:  Cell Mol Immunol       Date:  2010-09-27       Impact factor: 11.530

5.  Studies of the H60a locus in C57BL/6 and 129/Sv mouse strains identify the H60a 3'UTR as a regulator of H60a expression.

Authors:  Hui Zhang; Chanae Hardamon; Bright Sagoe; Jennifer Ngolab; Jack D Bui
Journal:  Mol Immunol       Date:  2010-11-19       Impact factor: 4.407

6.  Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice.

Authors:  Claire Godbersen-Palmer; Tiffany A Coupet; Zakaria Grada; Samuel C Zhang; Charles L Sentman
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

7.  NKG2D Ligands in Cancer Immunotherapy: Target or Not?

Authors:  Jennifer Wu
Journal:  Austin J Clin Immunol       Date:  2014-01-06

8.  Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands.

Authors:  Lola Fernández-Messina; Omodele Ashiru; Philippe Boutet; Sonia Agüera-González; Jeremy N Skepper; Hugh T Reyburn; Mar Valés-Gómez
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

Review 9.  Immunogenetics of the NKG2D ligand gene family.

Authors:  Masanori Kasahara; Shigeru Yoshida
Journal:  Immunogenetics       Date:  2012-07-29       Impact factor: 2.846

10.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.